Pharmacokinetic, Safety and Tolerability Study of Altebrel in Healthy Male Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

34 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-12-04

Study Completion Date

2017-03-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to demonstrate pharmacokinetic (PK) similarity of biosimilar candidate Altebrel relative to etanercept reference product (Enbrel®) and evaluate safety and tolerability of Altebrel, in a crossover fashion in healthy male volunteers after administration of a single dose (25 mg) of etanercept.

The primary objective of this study is to demonstrate that the PK of Altebrel is similar to its originator, Enbrel®, as assessed by the area under the serum concentration time curve (AUC) from time 0 extrapolated to infinity (AUCinf) and the Cmax.

The secondary objectives of the study are:

To further compare the PK of Altebrel and Enbrel®. To assess the safety of Altebrel.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bioequivalence Study of 2 Sizes of SHR4640 Tablets Orally in Healthy Subjects

NCT06168929

Hyperuricemia

COMPLETED PHASE1

Open-label Study Using 50 Mg Liquid Etanercept Subcutaneous Injection in the Thigh to Compare an Auto-injector Device and a Manual Injection in Healthy Subjects

NCT02588534

Healthy Men and Women

COMPLETED PHASE1

Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants

NCT02230046

Healthy

COMPLETED PHASE1

Bioequivalence Study of Atenolol 100mg Tablets Under Fasting Conditions

NCT00775580

Healthy

COMPLETED NA

Bioequivalence Study of Azilsartan Tablets in Chinese Healthy Volunteers

NCT03652792

Bioequivalence of Two Azilsartan Formulations

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a single-dose trial with one administration of each product (Altebrel and Enbrel®). Each subject participates in two treatment period, and are randomised to receive Altebrel or Enbrel® in a crossover fashion. The subjects are closely monitored during the following 24 hours (h), and are allowed to leave the site in the next morning post evaluation and blood samples are collected prior to and at the following time points after the dose: 6, 12 and 24 hours post-dose (on day 2). The subjects are requested to visit the trial site 36, 48, 60, 72, 96, 120, 144, 168, 216, 312 and 480 h after dose administration for blood sampling and evaluation of safety variable and tolerability.

Before initiation, the trial is reviewed by food and drug administration of Iran. The protocol, electronic case report form (eCRF), information for subjects and informed consent form are submitted to the ethics committees responsible for review and approval purposes, according to national regulatory guidelines.

In this study, no subject is recruited without an informed consent. All the informed consent forms which are signed by the subjects have two copies so that subjects could receive a copy of it.

This is a crossover trial with a single dose of Altebrel and Enbrel®, separated by 28 days. 34 (group A=17, group B=17) eligible subjects have been planned to enter to the study. All of whom are aged between 18 and 55 years. Subjects' randomization is done, using permuted block and subjects are assigned to treatment sequences AB or BA. Both groups receive 25 mg of either of the drugs as a single subcutaneous injection. The injection method and prefilled syringes are totally the same in both groups. The primary objective of this study is to demonstrate that the PK of Altebrel is similar to its originator, Enbrel®, as assessed by the area under the serum concentration time curve (AUC) from time 0 extrapolated to infinity (AUCinf) and the Cmax. Secondary objectives include assessment of the time to Cmax (tmax), AUC from time 0 to the last quantifiable concentration (AUClast) of Altebrel compared with Enbrel®, as well as evaluation of safety and tolerability. The safety endpoints of the trial are to evaluate the incidence of reported adverse effects, detecting changes in vital signs, clinical laboratory tests (hematologic, biochemistry, urine analysis and urine culture tests) and ECG.

Determination of sample size:

In an equivalence test of means using two one-sided tests on data from a two-period cross-over design, a total sample size of 34 achieves 81% power at a 10% significance level when the true ratio of the means is 1/0000, the coefficient of variation on the original, unlogged scale is 0/3600, and the equivalence limits of the mean ratio are 0/8000 and 1/2500.

DATA QUALITY ASSURANCE:

AryoGen pharmed Company conducts clinical trials according to procedures that incorporate the ethical principles of GCP. Accurate and reliable data collection was assured by verification and cross-check of the eCRFs against the subject's records by clinical monitors (source document verification was performed), and the maintenance of a drug-dispensing log by the center. A comprehensive validation check program was used to verify the data, and discrepancy reports were generated accordingly for resolution by the investigator.

Blinding:

This is a double-blind trial. During the clinical phase of the trial, neither the subjects nor the site personnel are aware of the identity (Altebrel and Enbrel®) of the treatments administered. However, there is an unblinded person who receives the randomisation list and dispenses the trial drugs according to the list. The unblinded person is not otherwise participate in the execution of the trial. The randomisation list determines the dispensing order of the trial products for each subject and only the randomisation number appear on the sample collection logs, as well as, on the sample aliquots delivered to the bioanalytical laboratory. Thus, the personnel responsible for analysing the PK samples are also be blinded.

Randomisation envelopes are stored in the ISF, in a locked cabinet. In a case of emergency, the code of an individual subject may be opened and the reasons for opening will be documented and the subject will be discontinued from the trial

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Phase 1 Bioequivalence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AryoGen Pharmed etanercept

Altebrel (etanercept prefilled syringe produced by AryoGen Pharmed Company) 25mg/0.5ml in prefilled syringe.

Group Type EXPERIMENTAL

Etanercept

Intervention Type DRUG

A single dose of etanercept (25mg/0.5ml prefilled syringe) was administered subcutaneously to healthy subjects.

Pfizer etanercept

Enbrel® (etanercept prefilled syringe produced by Pfizer Company) 25mg/0.5ml in prefilled syringe.

Group Type ACTIVE_COMPARATOR

Etanercept

Intervention Type DRUG

A single dose of etanercept (25mg/0.5ml prefilled syringe) was administered subcutaneously to healthy subjects.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Etanercept

A single dose of etanercept (25mg/0.5ml prefilled syringe) was administered subcutaneously to healthy subjects.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Altebrel Enbrel

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Provide written IC to participate in the trial and to comply with the trial procedures.

2\) Take written informed consent to participate in the trial and to abide by the trial restrictions.

3\) Be healthy male between the ages of 18 and 55 years. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, complete physical examination including blood pressure and heart rate measurement, 12 lead ECG and clinical laboratory tests.

4\) Have a body mass index between 20.0 and 29.9kg/m², inclusive 5) Have Chest X ray with no evidence of current, active TB or previous (inactive) TB, general infections, heart failure, malignancy, or other clinically significant abnormalities taken at Screening or within 24 weeks prior to Day 1 and read by a qualified radiologist

Exclusion Criteria

1. Being doubtful about their availability to complete the trial.
2. history and/or current presence of clinical significant atopic allergy, hypersensitivity or allergic reactions, also including known or suspected clinically relevant drug hypersensitivity to any components of the test and reference IMP formulation or comparable drugs.
3. Active or latent Tuberculosis or who have a history of Tuberculosis.
4. history of invasive systemic fungal infections or other opportunistic infections
5. systemic or local infection, a known risk for developing sepsis and/or known active inflammatory process
6. serious infection associated with hospitalisation and/or which required intravenous antibiotics
7. history of and/or current cardiac disease
8. Have received live vaccine(s) within 30 days prior to Screening or who will require live vaccine(s) between Screening and the final study visit.
9. Intake medication with a half-life \> 24 h within 1 month or 5 half-lives of the medication prior to the first administration of IMP.
10. Positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody. A positive test for HIV antibody.
11. History of CNS demyelinating disorders in family (MS)
12. Have a history of smoking \>10 cigarettes per day

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes